November 1, 2023 07:20 AM EDT
Deals
Cell/Gene Tx

As­traZeneca pays $25M up­front, $80M eq­ui­ty in­vest­ment in­to Cel­lec­tis for gene and cell ther­a­py pact

Katherine Lewin

News Reporter

As­traZeneca is beef­ing up its cell and gene ther­a­py po­ten­tial by col­lab­o­rat­ing with and in­vest­ing in French biotech Cel­lec­tis, start­ing out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times